MDxHealth SA is a precision diagnostics company that focuses on developing and commercializing innovative molecular tests to support the diagnosis, prognosis, and monitoring of cancer. Through its proprietary technology and advanced genomic profiling, the company aims to provide healthcare professionals with critical insights into patient conditions, ultimately enhancing personalized treatment strategies. MDxHealth’s products are designed to improve patient outcomes by offering more accurate and reliable information that assists in clinical decision-making in oncology. Read More
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.
Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET
Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET
